Technology

Linus Health to Demonstrate How Digital Health Powers Innovation at Clinical Trials on Alzheimer’s Disease (CTAD)

Published

2 months ago

October 29, 2024

Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers best-in-class outcomes assessments for streamlined and meaningful clinical trials

MADRID, Oct. 29, 2024 /PRNewswire/ — Clinical and research leaders from Linus Health, a digital health company enabling early detection of Alzheimer’s and other dementias, will deliver four poster presentations at a pre-eminent international conference on Alzheimer’s disease taking place this week.

Linus Health leaders will present their findings at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, which runs today through this Friday, Nov. 1, in Madrid, Spain. The conference is expected to attract 2,200 leading experts onsite and online to discuss the latest therapeutic advances in Alzheimer’s disease. Scientists from across the globe will present clinical trial results and new therapeutic strategies to treat people experiencing all stages of the disease, as well as the latest on Alzheimer’s prevention.

Posters from Linus Health and other researchers will be on display for in-person viewing on Nov. 1 from 7:15 a.m. to 5 p.m. Central European Time (6 hours ahead of Eastern Standard Time). All posters are also accessible via the CTAD24 digital platform.

“It is a privilege to be invited to present four poster presentations at such a prestigious conference that attracts a large, global audience,” said Linus Health CEO David Bates, PhD. “This honor certainly demonstrates the quality and relevancy of our research. It is also an indicator that the leaders in the field of Alzheimer’s disease and related dementias recognize the growing value of augmenting human clinical expertise with innovative technology to deliver much broader insight into cognitive function with greater efficiency.”

Linus Health poster presentations include:

“Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning Enabled Digital Cognitive Assessment.” Findings from Director of Cognitive Science Linus Health Ali Jannati, MD, PhD, show that the accuracy of Linus Health’s Digital Clock and Recall™ (DCR™) platform matched blood-based biomarkers in predicting cognitive impairment and were superior or comparable to traditional cognitive tests. The results demonstrate that the DCR effectively streamlines recruitment for clinical trials, offers a cost-effective solution for selecting suitable participants, and reduces screen failure rates.”Incorporating personally defined brain health priorities in clinical trials outcomes: the electronic Person Specific Outcome Measure approach in the U.S.” This study by Chief Medical Officer Alvaro Pascual-Leone, MD, PhD, found heterogeneity in individual-level brain health priorities in the United States. The findings indicate that self-reported confidence in managing personally meaningful priorities may be an appropriate construct to incorporate the person’s voice in study outcomes. They also suggest that Linus Health’s electronic Person Specific Outcome Measure tool supports the establishment of clinical meaningfulness in Alzheimer’s disease trials and is now being validated in other global populations.”Identification of Cognitive Impairment in Alzheimer’s Disease with Drawing and Speech-Based Assessments and Metrics.” The poster from Data Scientist Tanya Talkar, PhD, showcases the benefits of combining speech- and linguistic-based metrics with drawing- and process-based metrics in screening for cognitive impairment. Since the screening can be administered both in the clinic and remotely, it offers researchers accessible, repeated recordings to screen for clinical trials or evaluation of disease-modifying therapies.”Digital Assessment of Cognition for Optimizing Neuropsychology Workflow.” Jannati is presenting another study he led that proposes a workflow involving a technology-enabled psychometry assistant (TPA), a medical assistant equipped with the Linus Health Core Cognitive Evaluation (CCE) and Clinical Decision Support (CDS) system, to streamline the initial cognitive assessment process at the primary care level. The proposed workflow significantly improved the efficiency of neuropsychological evaluations by reducing the workload of specialists, avoiding unnecessary referrals, and prioritizing those that need further assessment.

The 17th annual CTAD conference will take place at the Madrid Marriott Auditorium Hotel and Conference Center, and via the CTAD virtual platform.

To learn more about Linus Health’s research and solutions for clinical trials, or to take a closer look at our platform’s suite of digital assessments, click here.

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health, visit www.linushealth.com or follow us on LinkedIn.

Media Contact
Tara Stultz
Amendola for Linus Health
440-225-9595
tstultz@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on-alzheimers-disease-ctad-302289415.html

SOURCE Linus Health

Technology

PEAK6 to Relocate Global Headquarters to Austin, Texas

Published

17 minutes ago

December 27, 2024

CHICAGO, Dec. 27, 2024 /PRNewswire/ — PEAK6 Investments LLC (“PEAK6”) today announced that, effective January 1, 2025, it will move its global headquarters from its current location in Chicago, Illinois to the company’s existing office in Austin, Texas, which it established in 2021. PEAK6 affiliates PEAK6 Group LLC, PEAK6 Strategic Capital LLC, PEAK6 APX Holdings LLC and PEAK6 LLC will also relocate their global headquarters to Austin. PEAK6 will maintain its office in Chicago.

“Texas has been a cornerstone of PEAK6’s growth for over a decade,” said PEAK6 Co-Founder and Co-CEO, Matt Hulsizer, who continued, “With the majority of our talented workforce now based in Texas and Austin emerging as our largest office, moving our headquarters was an important decision to be closer to our team. We’re excited for the next chapter of PEAK6 that will be written from our new headquarters.”

Austin’s unique blend of creativity, technology and culture provides the ideal environment for PEAK6. The city’s highly educated workforce, business climate, and strong entrepreneurial spirit have enabled us to attract top talent and drive innovation.

About PEAK6

PEAK6 uses technology to find a better way of doing things. The company’s first tech-based solution was developed in 1997 to optimize options trading, and over the past two decades, the same formula has been used across a range of industries, asset classes, and business stages to consistently deliver superior results. Today, PEAK6 seeks transformational opportunities to provide capital and strategic support to entrepreneurs and forward-thinking businesses.

PEAK6’s core brands include PEAK6 Capital Management, PEAK6 Strategic Capital, Apex Fintech Solutions, We Insure, FOCUS, Zogo, Evil Geniuses and Poker Power.

View original content to download multimedia:https://www.prnewswire.com/news-releases/peak6-to-relocate-global-headquarters-to-austin-texas-302339437.html

SOURCE PEAK6 Investments

Technology

Zero Zero Robotics showcases bestselling HOVERAir X1 series at CES 2025

Published

17 minutes ago

December 27, 2024

Redefining motion capture with innovative flying action cameras and the award-winning HOVERAir Beacon

LAS VEGAS, Dec. 27, 2024 /PRNewswire/ — Recently, Zero Zero Robotics, a pioneering tech company in intelligent devices, announced their participation at CES 2025, where the company will showcase its HOVERAir X1 series of self-flying cameras at booth # 56045, Venetian, Level 2, Halls A-D. Designed to simplify aerial cinematography, the HOVERAir lineup includes the pocket-sized HOVERAir X1, the action-focused HOVERAir X1 PRO, and the Professional grade HOVERAir X1 PROMAX. Zero Zero will also celebrate its 2025 CES Innovation Awards Honoree title in Audio/Video Components & Accessories for the HOVERAir Beacon, an intelligent modular controller that redefines precision tracking and control.

The introductory model in the HOVERAir lineup, HOVERAir X1, weighs just 125g and delivers an effortless aerial photography experience with no controller or app required. With over five pre-programmed flight paths, including Hover, Follow, Zoom Out, Orbit, and Bird’s Eye, it’s perfect for capturing cinematic moments in everyday life. Its 2.7K video resolution, palm launch capabilities, and robust computer vision algorithms make it the ultimate everyday and travel companion.

Building on the success of the X1, Zero Zero introduced the HOVERAir X1 PRO and HOVERAir X1 PROMAX in August 2024 to meet the demands of action enthusiasts and professional creators. The X1 PRO offers 4K/60fps video with a 104° field of view for versatile shooting conditions. The X1 PROMAX delivers stunning 8K/30fps video with 4K/120fps slow-motion capabilities, a 1/1.3″ CMOS sensor, and 14 stops of dynamic range for cinematic footage. Both models feature advanced AI tracking, Level 5 wind resistance, and a lightweight, durable HEM™ frame.

“Our vision has always been to create flying cameras that are effortless, intelligent, and fun to use,” said MQ Wang, Founder & CEO of Zero Zero Robotics. “The HOVERAir series puts professional-grade aerial cinematography in the palm of your hand, whether you’re capturing casual moments or pushing creative boundaries.”

Adding to these innovations, the HOVERAir Beacon enhances control and precision for the series. The Beacon features a patented Tri-state modular design with two detachable joysticks, enabling one-handed and full-featured two-handed controls. It activates HoverLink™ for precise tracking with up to a 1 km transmission range, while the 1.78″ OLED display allows real-time footage monitoring. Equipped with AI-powered noise cancellation, the Beacon sets a new standard for audio and video recording during aerial shoots.

“We’re excited to bring the HOVERAir X1 series and Beacon to CES 2025, where we’re redefining how motion is captured, tracked, and controlled,” continued Wang. “These tools empower creators and adventurers to document their journeys with breathtaking precision and ease.”

Zero Zero Robotics invites attendees to stop by Booth #56045 to experience the HOVERAir X1 series in action and witness its unparalleled performance. Media wishing to interview Zero Zero Robotics personnel should contact Borjana Slipicevic.

About Zero Zero Robotics

Zero Zero Robotics was co-founded in 2014 by Stanford PhDs MQ Wang and Tony Zhang, specializing in embedded AI technology for intelligent devices. Known for its innovative machine vision and high-precision control systems, ZeroZero has team members who are dreamers, engineers, inventors, and builders hailing from top universities and research institutions around the world. Zero Zero Robotics holds more than 140 core patents and has pioneered technologies like fully enclosed portable propeller designs and bi-copter designs, cementing its place as a leader in intelligent device development.

Photo – https://mma.prnewswire.com/media/2587719/20241225_CES.jpg

View original content:https://www.prnewswire.co.uk/news-releases/zero-zero-robotics-showcases-bestselling-hoverair-x1-series-at-ces-2025-302339226.html

Technology

ResumeTemplates.com Survey Reveals 3 in 10 Gen Zers Believe CEOs Are Evil; Many Support Release of Mangione

Published

1 hour ago

December 27, 2024

The majority of Gen Zers feel CEOs wield excessive power, with some expressing extreme views about corporate accountability

SEATTLE, Dec. 27, 2024 /PRNewswire-PRWeb/ — ResumeTemplates.com, the leading platform for professional resume templates and career advice, has released findings from a recent survey revealing critical attitudes among Gen Z toward corporate leaders. Conducted in December 2024, the survey of 1,200 U.S.-based Gen Zers highlights the sentiment that CEOs hold excessive power and are overcompensated, with some respondents expressing extreme views about corporate accountability.

According to the survey, more than half of Gen Zers (55%) believe CEOs wield excessive power in society, particularly influencing elections, the economy, and policymaking. Additionally, 59% of respondents believe CEOs are overpaid, with most saying total annual compensation should not exceed $750,000. Only 7% of respondents support unlimited earning potential for CEOs. The survey also found that 39% of Gen Zers believe all levels of a workforce equally contribute to a company’s success, while only 20% think CEOs create the most value within an organization.

The survey also explored Gen Z’s perceptions of corporate leadership. More than half believe CEOs are responsible for driving corporate greed, and 30% of respondents view CEOs as “evil,” reflecting deep skepticism toward corporate leadership.

Additionally, the survey examined opinions on high-profile cases like Brian Thompson’s killing. Among respondents, 21% agreed that “CEOs deserve to lose their lives for their professional actions,” including 7% who strongly agreed. When asked specifically about Brian Thompson’s killing, 22% of respondents believe he definitely (10%) or probably (12%) deserved what happened to him. Regarding Luigi Mangione, Thompson’s accused killer, 21% supported his release, while 51% opposed it.

This survey, conducted December 18, 2024, via Pollfish, gathered responses from 1,200 U.S.-based 18 to 27 year olds. The full report can be viewed here: https://www.resumetemplates.com/3-in-10-gen-zers-say-ceos-are-evil-many-believe-mangione-should-go-free/

ABOUT RESUMETEMPLATES.COM
ResumeTemplates.com offers a comprehensive selection of free, industry-specific resume templates, tailored to meet the needs of various job seekers. The website also provides extensive resources to help facilitate the job application process, including expert advice, resume examples, and tips and tricks for creating impactful resumes. For more information, please visit: https://www.resumetemplates.com/.

Media Contact

Abigail Davis, ResumeTemplates, 000-0000, abigail@resumetemplates.com

View original content:https://www.prweb.com/releases/resumetemplatescom-survey-reveals-3-in-10-gen-zers-believe-ceos-are-evil-many-support-release-of-mangione-302338434.html

SOURCE ResumeTemplates